非酒精性脂肪肝与代谢综合征各组分关系的研究进展

Abstract
Figure/Table
References (45)
Related Citation (15)

Download: PDF (865 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Non-alcoholic fatty liver disease (NAFLD) can be divided into primary and secondary categories. The former is related to insulin resistance and genetic susceptibility, while the latter is caused by some special reasons. Excessive weight gain and overweight caused by excess nutrition, obesity, diabetes, hyperlipidemia and other metabolic syndrome-related fatty liver are secondary NAFLD category. With the trend of globalization of metabolic syndrome,NAFLD has become an important cause of chronic liver disease in developed countries such as Europe and the United States and rich areas of China. In addition to directly leading to decompensated cirrhosis, hepatocellular carcinoma and liver transplantation recurrence, NAFLD can also affect the progression of other chronic liver diseases and be involved in the pathogenesis of type 2 diabetes and atherosclerosis. Malignant tumors associated with metabolic syndrome, arteriosclerotic cardiovascular and cerebrovascular diseases, and cirrhosis are important factors affecting the quality of life and life expectancy of NAFLD patients. Therefore, NAFLD is a new challenge in the field of modern medicine, and the harm of NAFLD to human health will continue to increase in the near future. This paper reviews the relationship between NAFLD and various components of metabolic syndrome, including obesity, hyperglycemia, dyslipidemia and hypertension, by reviewing relevant literatures at home and abroad, aiming to provide reference for early warning and intervention of patients with non-alcoholic fatty liver disease.

Key words： Nonalcoholic fatty liver disease Metabolic syndrome Mutual cause and effect Review

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Yuanyuan
	JIANG Jianping

Cite this article:

WANG Yuanyuan,JIANG Jianping. Research progress of the relationship between nonalcoholic fatty liver disease and components of metabolic syndrome[J]. 中国当代医药, 2022, 29(15): 36-39转43.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2022/V29/I15/36

[1]	Diehl AM，Day C.Cause，Pathogenesis，and Treatment of Nonalcoholic Steatohepatitis[J].N Engl J Med，2017，377（21）：2063-2072.
[2]	Rinella ME.Nonalcoholic fatty liver disease：a systematic review[J].JAMA，2015，313（22）：2263-2273.
[3]	Hashimoto E，Tokushige K，Ludwig J.Diagnosis and classification of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis：Current concepts and remaining challenges[J].Hepatol Res，2015，45（1）：20-28.
[4]	Younossi Z，Anstee Q M，Marietti M，et al.Global burden of NAFLD and NASH：trends，predictions，risk factors and prevention[J].Nat Rev Gastroenterol Hepatol，2018，15（1）：11-20.
[5]	Mantovani A，Scorletti E，Mosca A，et al.Complications，morbidity and mortality of nonalcoholic fatty liver disease[J].Metabolism，2020，111S：154170.
[6]	Zhou F，Zhou J，Wang W，et al.Unexpected Rapid Increase in the Burden of NAFLD in China From 2008 to 2018：A Systematic Review and Meta-Analysis[J].Hepatology，2019，70（4）：1119-1133.
[7]	Estes C，Anstee QM，Arias-Loste MT，et al.Modeling NAFLD disease burden in China，France，Germany，Italy，Japan，Spain，United Kingdom，and Un ited States for the period 2016-2030[J].J Hepatol，2018，69（4）：896-904.
[8]	中国成人血脂异常防治指南制订联合委员会.中国成人血脂异常防治指南[J].中华心血管病杂志，2007，35（5）：390-419.
[9]	Younossi ZM，Koenig AB，Abdelatif D，et al.Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence，incidence，and outcomes[J].Hepatology，2016，64（1）：73-84.
[10]	Xu ZJ，Shi JP，Yu DR，et al.Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non -Alcoholic Steatohepatitis in China：A Multicenter Cross-Sectional Study Design[J].Adv Ther，2016，33（11）：2069-2081.
[11]	Younossi ZM，Koenig AB，Abdelatif D，et al.Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence，incidence，and outcomes[J].Hepatology，2016，64（1）：73-84.
[36]	刘园，贺鹍鹏，强艳，等.某体检人群非酒精性脂肪肝的现状及其与高脂血症、肝功能异常的关系[J].宁夏医科大学学报，2015，37（3）：267-271.
[39]	Poynard T，Ratziu V，Naveau S，et al.The diagnostic value of biomarkers （SteatoTest）for the prediction of liver steatosis[J].Comp Hepatol，2005，4：10.
[40]	Kim D，Touros A，Kim WR.Nonalcoholic Fatty Liver Disease and Metabolic Syndrome[J].Clin Liver Di，2018，22（1）：133-140.
[12]	Geurtsen ML，Santos S，Felix JF，et al.Liver fat and cardio-metabolic risk factors among school age children[J].Hepatology，2020，72（1）：119-129.
[13]	Alexander M，Loomis AK，van der Lei J，et al.Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD：real-world study of 18 million patients in four European cohorts[J].BMC Med，2019，17（1）：95.
[14]	Stefan N，Haring HU，Cusi K.Non-alcoholic fatty liver disease：causes，diagnosis，cardiometabolic consequences，and treatment strategies[J].Lancet Diabetes Endocrinol，2019，7（4）：313-324.
[15]	Schwimmer JB，Pardee PE，Lavine JE，et al.Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease[J].Circulation，2008，118（3）：277-283.
[16]	沈凌，孙星.非酒精性脂肪性肝病相关的肝细胞癌发病机制的研究进展[J].中华肝胆外科杂志，2019，25（9）：707-710.
[17]	Xu E，Pereira M，Karakasilioti I，et al.Temporal and tissue-specific requirements for T-lymphocyte IL-6 signalling in obesity-associated inflammation and insulin resistance[J].Nat Commun，2017，8：14803.
[18]	阎利萍，左吉卉，吴明江，等.脂肪酸代谢与非酒精性脂肪肝疾病关系的研究进展[J].中国医药科学，2020，10（20）：35-39，56.
[19]	Byrne C D，Targher G.NAFLD：a multisystem disease[J].J Hepatol，2015，62：S47-S64.
[20]	袁颖，丁芳.非酒精性脂肪肝危险因素分析及护理干预[J].护理研究，2016，30（27）：3380-3381.
[21]	Younossi ZM.Non-alcoholic fatty liver disease-A global public health perspective[J].J Hepatol，2019，70（3）：531-544.
[22]	Hagstrom H，Stal P，Hultcrantz R，et al.Overweight in late adolescence predicts development of severe liver disease later in life：A 39years follow-up study[J].J Hepatol，2016，65（2）：363-368.
[23]	Marin-Alejandre BA，Abete I，Cantero I，et al.Association between Sleep Disturbances and Liver Status in Obese Subjects with Nonalcoholic Fatty Liver Disease：A Comparison with Healthy Controls[J].Nutrients，2019，11（2）：322.
[24]	Targher G，Marchesini G，Byrne CD.Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease：Causal association or epiphenomenon?[J].Diabetes Metab，2016，42（3）：142-156.
[25]	McPherson S，Hardy T，Henderson E，et al.Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies：implications for prognosis and clinical management[J].J Hepatol，2015，62（5）：1148-1155.
[27]	张荣，陈侃，夏玉敬，等.二甲双胍治疗非酒精性脂肪性肝病合并糖尿病的研究进展[J].世界临床药物，2016，37（3）：214-216.
[33]	马振增，陆伦根.胆固醇代谢与非酒精性脂肪性肝炎[J].中华肝脏病杂志，2016，24（8）：623-627.
[34]	Ioannou GN.The Role of Cholesterol in the Pathogenesis of NASH[J].Trends Endocrinol Metab，2016，27（2）：84-95.
[26]	Younossi Z M，Golabi P，de Avila L，et al.The global epidemiology of NAFLD and NASH in patients with type 2 diabetes：A systematic review and meta-analysis[J].J Hepatol，2019，71（4）：793-801.
[28]	Mantovani A，Byrne CD，Bonora E，et al.Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes：A Meta-analysis[J].Diabetes Care，2018，41（2）：372-382.
[29]	Musso G，Gambino R，Cassader M，et al.Meta-analysis：natural history of non-alcoholic fatty liver disease （NAFLD）and diagnostic accuracy of non-invasive tests for liver disease severity[J].Ann Med，2011，43：617-649.
[30]	Nobili V，Mantovani A，Cianfarani S，et al.Prevalence of prediabetes and diabetes in children and adolescents with biopsy-proven non-alcoholic fatty liver disease[J].J Hepatol，2019，71（4）：802-810.
[31]	Watanabe S，Hashimoto E，Ikejima K，et al.Evidence -based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis[J].J Gastroenterol，2015，50（4）：364-377.
[32]	Zhang QQ，Lu LG.Nonalcoholic Fatty Liver Disease：Dyslipidemia，Risk for Cardiovascular Complications，and Treatment Strategy[J].J Clin Transl Hepatol，2015，3（1）：78-84.
[35]	Wong VW，Adams LA，de Lédinghen V，et al.Noninvasive biomarkers in NAFLD and NASH-current progress and future promise[J].Nat Rev Gastroenterol Hepatol，2018，15（8）：461-478.
[37]	Yip TC，Ma AJ，Wong VW，et al.Laboratory parameterbased machine learning model for excluding non-alcoholic fatty liver disease （NAFLD） in the general population[J].Aliment Pharmacol Ther，2017，46（4）：447-456.
[38]	Poynard T，Ratziu V，Charlotte F，et al.Diagnostic value of biochemical markers （NashTest） for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease[J].BMC Gastroenterol，2006，6：34.
[41]	Lonardo A，Nascimbeni F，Mantovani A，et al.Hypertension，diabetes，atherosclerosisandNASH：Causeorconsequence?[J].J Hepatol，2018，68（2）：335-352.
[42]	Ryoo JH，Ham WT，Choi JM，et al.Clinical significance of non-alcoholic fatty liver disease as a risk factor for prehypertension[J].J Korean Med Sci，2014，29（7）：973-979.
[43]	Ekstedt M，Hagstrpagenumber_ebook=49,pagenumber_book=43 m H，Nasr P，et al.Fibrosis stage is the strongest predictor for disease -specific mortality in NAFLD after up to 33 years of follow-up[J].Hepatology，2015，61（5）：1547-1554.
[44]	Aneni EC，Oni ET，Martin SS，et al.Blood pressure is associated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of cardiometabolic risk[J].J Hypertens，2015，33（6）：1207-1214.
[45]	夏换兰，陆标明，何凤平，等.佛山市三水区体检人群非酒精性脂肪肝流行病学调查及相关危险因素分析[J].解放军预防医学杂志，2020，38（1）：50-52.